Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' BUKOWSKI RM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 99 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Motzer, RJ; Rakhit, A; Thompson, JA; Nemunaitis, J; Murphy, BA; Ellerhorst, J; Schwartz, LH; Berg, WJ; Bukowski, RM
      Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma

      JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    2. Finke, JH; Rayman, P; George, R; Tannenbaum, CS; Kolenko, V; Uzzo, R; Novick, AC; Bukowski, RM
      Tumor-induced sensitivity to apoptosis in T cells from patients with renalcell carcinoma: Role of nuclear factor-kappa B suppression

      CLINICAL CANCER RESEARCH
    3. Tate, J; Olencki, T; Finke, J; Kottke-Marchant, K; Rybicki, LA; Bukowski, RM
      Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: Clinical and laboratory effects

      ANNALS OF ONCOLOGY
    4. Olencki, T; Peereboom, D; Wood, L; Budd, GT; Novick, A; Finke, J; McLain, D; Elson, P; Bukowski, RM
      Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    5. Tabata, M; Tabata, R; Grabowski, DR; Bukowski, RM; Ganapathi, MK; Ganapathi, R
      Roles of NF-kappa B and 26 S proteasome in apoptotic cell death induced bytopoisomerase I and II poisons in human nonsmall cell lung carcinoma

      JOURNAL OF BIOLOGICAL CHEMISTRY
    6. Aoyama, M; Grabowski, DR; Holmes, KA; Rybicki, LA; Bukowski, RM; Ganapathi, MK; Ganapathi, R
      Cell cycle phase specificity in the potentiation of etoposide-induced DNA damage and apoptosis by KN-62, an inhibitor of calcium-calmodulin-dependentenzymes

      BIOCHEMICAL PHARMACOLOGY
    7. Olencki, T; Finke, J; Tubbs, R; Elson, P; McLain, D; Herzog, P; Budd, GT; Gunn, H; Bukowski, RM
      Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: Clinical and biologic effects

      JOURNAL OF IMMUNOTHERAPY
    8. Rayman, P; Uzzo, RG; Kolenko, V; Bloom, T; Cathcart, MK; Molto, L; Novick, AC; Bukowski, RM; Hamilton, T; Finke, JH
      Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: A mechanism of immune escape

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    9. Pelley, R; Ganapathi, R; Wood, L; Rybicki, L; McLain, D; Budd, GT; Peereboom, D; Olencki, T; Bukowski, RM
      A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    10. Bukowski, RM
      Cytokine combinations: Therapeutic use in patients with advanced renal cell carcinoma

      SEMINARS IN ONCOLOGY
    11. Uzzo, RG; Rayman, P; Novick, AC; Bukowski, RM; Finke, JAH
      Molecular mechanisms of immune dysfunction in renal cell carcinoma

      RENAL CELL CARCINOMA
    12. Bukowski, RM
      Adjuvant therapy of renal cell carcinoma

      RENAL CELL CARCINOMA
    13. Olencki, T; Bukowski, RM
      Interleukin-2 in metastatic renal cell carcinoma

      RENAL CELL CARCINOMA
    14. Ulchaker, J; Panuto, J; Rayman, P; Novick, A; Elson, P; Tubbs, R; Finke, JH; Bukowski, RM
      Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion in response to interleukin-12

      JOURNAL OF IMMUNOTHERAPY
    15. Bukowski, RM; Rayman, P; Molto, L; Tannenbaum, CS; Olencki, T; Peereboom, D; Tubbs, R; McLain, D; Budd, GT; Griffin, T; Novick, A; Hamilton, TA; Finke, J
      Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma

      CLINICAL CANCER RESEARCH
    16. Bukowski, RM
      Immunotherapy in renal cell carcinoma

      ONCOLOGY-NEW YORK
    17. Bukowski, RM
      Chemoimmunotherapy of metastatic renal cell carcinoma

      CANCER INVESTIGATION
    18. Figlin, RA; Thompson, JA; Bukowski, RM; Vogelzang, NJ; Novick, AC; Lange, P; Steinberg, GD; Belldegrun, AS
      Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

      JOURNAL OF CLINICAL ONCOLOGY
    19. Budd, GT; Ganapathi, R; Wood, L; Snyder, J; McLain, D; Bukowski, RM
      Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine

      SEMINARS IN ONCOLOGY
    20. Plautz, GE; Bukowski, RM; Novick, AC; Klein, EA; Kursh, ED; Olencki, TE; Yetman, RJ; Pienkny, A; Sandstrom, K; Shu, SY
      T-cell adoptive immunotherapy of metastatic renal cell carcinoma

      UROLOGY
    21. Grabowski, DR; Holmes, KA; Aoyama, M; Ye, Y; Rybicki, LA; Bukowski, RM; Ganapathi, MK; Hickson, ID; Ganapathi, R
      Altered drug interaction and regulation of topoisomerase II beta: Potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide

      MOLECULAR PHARMACOLOGY
    22. Uzzo, RG; Rayman, P; Kolenko, V; Clark, PE; Cathcart, MK; Bloom, T; Novick, AC; Bukowski, RM; Hamilton, T; Finke, JH
      Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappa B activation in T cells

      JOURNAL OF CLINICAL INVESTIGATION
    23. Uzzo, RG; Clark, PE; Rayman, P; Bloom, T; Rybicki, L; Novick, AC; Bukowski, RM; Finke, JH
      Alterations in NF kappa B activation in T lymphocytes of patients with renal cell carcinoma

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    24. Bukowski, RM
      Therapeutic use of recombinant proteins

      BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT
    25. AOYAMA M; MACISAAC D; BUKOWSKI RM; GANAPATHI MK
      INTERLEUKIN-6 DIFFERENTIALLY POTENTIATES THE ANTITUMOR EFFECTS OF TAXOL AND VINBLASTINE IN U266 HUMAN MYELOMA CELLS

      Clinical cancer research
    26. AOYAMA M; MACISAAC D; BUKOWSKI RM; GANAPATHI MK
      INTERLEUKIN-6 DIFFERENTIALLY POTENTIATES THE ANTITUMOR EFFECTS OF TAXOL AND VINBLASTINE IN U266 HUMAN MYELOMA CELLS

      Clinical cancer research
    27. BUDD GT; ADAMSON PC; GUPTA M; HOMAYOUN P; SANDSTROM SK; MURPHY RF; MCLAIN D; TUASON L; PEEREBOOM D; BUKOWSKI RM; GANAPATHI R
      PHASE I II TRIAL OF ALL-TRANS-RETINOIC ACID AND TAMOXIFEN IN PATIENTSWITH ADVANCED BREAST-CANCER/

      Clinical cancer research
    28. BUDD GT; ADAMSON PC; GUPTA M; HOMAYOUN P; SANDSTROM SK; MURPHY RF; MCLAIN D; TUASON L; PEEREBOOM D; BUKOWSKI RM; GANAPATHI R
      PHASE I II TRIAL OF ALL-TRANS-RETINOIC ACID AND TAMOXIFEN IN PATIENTSWITH ADVANCED BREAST-CANCER/

      Clinical cancer research
    29. BUKOWSKI RM; RAYMAN P; UZZO R; BLOOM T; SANDSTROM K; PEEREBOOM D; OLENCKI T; BUDD GT; MCLAIN D; ELSON P; NOVICK A; FINKE JH
      SIGNAL-TRANSDUCTION ABNORMALITIES IN T-LYMPHOCYTES FROM PATIENTS WITHADVANCED RENAL-CARCINOMA - CLINICAL RELEVANCE AND EFFECTS OF CYTOKINETHERAPY

      Clinical cancer research
    30. BENNETT CL; GOLUB RM; CALHOUN EA; WEINSTEIN J; FISHMAN D; LURAIN J; ROLAND P; MEDIO F; BUKOWSKI RM
      COST-UTILITY ASSESSMENT OF AMIFOSTINE AS FIRST-LINE THERAPY FOR OVARIAN-CANCER

      International journal of gynecological cancer
    31. GANAPATHI MK; AOYAMA M; GANAPATHI R; BUKOWSKI RM; MACLSAAC D
      INTERLEUKIN-6 DIFFERENTIALLY POTENTIATES THE ANTITUMOR EFFECTS OF TAXOL AND VINBLASTINE IN THE HUMAN MYELOMA CELLS, U266

      Annals of oncology
    32. BUKOWSKI RM; OLENCKI T; BOCOCK K; BUDD GT; PEEREBOOM D; MCLAIN D; GRIFFIN T
      PHASE-I TRIAL OF CAPECITABINE AND SUBCUTANEOUS INTERFERON-ALPHA IN RENAL-CELL CARCINOMA (RCC)

      Annals of oncology
    33. Aoyama, M; Grabowski, DR; Dubyak, GR; Constantinou, AI; Rybicki, LA; Bukowski, RM; Ganapathi, MK; Hickson, ID; Ganapathi, R
      Attenuation of drug-stimulated topoisomerase II DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium bufferis correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase II alpha

      BIOCHEMICAL JOURNAL
    34. KRISHNAMURTHI V; NOVICK AC; BUKOWSKI RM
      EFFICACY OF MULTIMODALITY THERAPY IN ADVANCED RENAL-CELL CARCINOMA

      Urology
    35. PIENKNY AJ; NOVICK AC; PLAUTZ GE; OLENCKI T; SANDSTROM K; BUKOWSKI RM; SHU S
      PHASE-I TRIAL OF ADOPTIVE IMMUNOTHERAPY FOR METASTATIC RENAL-CELL CARCINOMA WITH ACTIVATED LYMPH-NODE T-LYMPHOCYTES

      The Journal of urology
    36. RAYMAN P; CLARK PE; UZZO RG; NOVICK AC; BUKOWSKI RM; FINKE JH
      IMPAIRED T-CELL ACTIVATION IN A SUBSET OF PATIENTS WITH RENAL-CELL CARCINOMA IS SECONDARY TO IMPAIRED DEGRADATION OF I-KAPPA-B-BETA OR I-KAPPA-B-EPSILON

      The Journal of urology
    37. TANNENBAUM CS; TUBBS R; ARMSTRONG D; FINKE JH; BUKOWSKI RM; HAMILTON TA
      THE CXC CHEMOKINES IP-10 AND MIG ARE NECESSARY FOR IL-12-MEDIATED REGRESSION OF THE MOUSE RENCA TUMOR

      The Journal of immunology (1950)
    38. AOYAMA M; GRABOWSKI DR; ISAACS RJ; KRIVACIC KA; RYBICKI LA; BUKOWSKI RM; GANAPATHI MK; HICKSON ID; GANAPATHI R
      ALTERED EXPRESSION AND ACTIVITY OF TOPOISOMERASES DURING ALL-TRANS-RETINOIC ACID-INDUCED DIFFERENTIATION OF HL-60 CELLS

      Blood
    39. KUDOH S; REDOVAN C; RAYMAN P; EDINGER M; TUBBS RR; NOVICK A; FINKE JH; BUKOWSKI RM
      DEFECTIVE GRANZYME-B GENE-EXPRESSION AND LYTIC RESPONSE IN T-LYMPHOCYTES INFILTRATING HUMAN RENAL-CELL CARCINOMA

      Journal of immunotherapy
    40. BUKOWSKI RM; OLENCKI T; WANG Q; PEEREBOOM D; BUDD GT; ELSON P; SANDSTROM K; TUASON L; RAYMAN P; TUBBS R; MCLAIN D; KLEIN E; NOVICK A; FINKE J
      PHASE-II TRIAL OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN PATIENTS WITHRENAL-CELL CARCINOMA - CLINICAL-RESULTS AND IMMUNOLOGICAL CORRELATES OF RESPONSE

      Journal of immunotherapy with emphasis on tumor immunology
    41. BUKOWSKI RM; NOVICK RM
      CLINICAL-PRACTICE GUIDELINES - RENAL-CELL CARCINOMA (VOL 64, PG SI-29, 1997)

      Cleveland Clinic journal of medicine
    42. BUKOWSKI RM
      NATURAL-HISTORY AND THERAPY OF METASTATIC RENAL-CELL CARCINOMA - THE ROLE OF INTERLEUKIN-2

      Cancer
    43. BUDD GT; GANAPATHI R; ADELSTEIN DJ; PELLEY R; OLENCKI T; PETRUS J; MCLAIN D; ZHANG JL; CAPIZZI R; BUKOWSKI RM
      RANDOMIZED TRIAL OF CARBOPLATIN PLUS AMIFOSTINE VERSUS CARBOPLATIN ALONE IN PATIENTS WITH ADVANCED SOLID TUMORS

      Cancer
    44. HUSSEIN MA; WOOD L; MCLAIN D; BUKOWSKI RM
      DOXIL(R), VINCRISTINE AND DECADRON (DVD) IN THE MANAGEMENT OF MULTIPLE-MYELOMA (MM) PATIENTS (PTS) - A PRELIMINARY-REPORT

      Blood
    45. HUSSEIN MA; SNYDER J; FINKE J; RAYMAN P; MCLAIN D; ELSON P; BUKOWSKI RM
      THE EFFECT OF IL-2 MAINTENANCE (MN) THERAPY (TX) ON THE DURATION OF THE PLATEAU-PHASE IN RESPONDING MULTIPLE-MYELOMA (MM) PATIENTS (PTS)

      Blood
    46. HUSSEIN MA; ZUCCARO K; BLOOM T; FINKE J; ELSON P; BUKOWSKI RM
      HIGH-DOSE ALL-TRANS-RETINOIC ACID (ATRA) IN MULTIPLE-MYELOMA (MM)

      Blood
    47. FINKE J; MOLTO L; BLOOM T; KOLENKO V; POHLMAN B; LICHTIN A; MCLAIN D; TUBBS R; BUKOWSKI RM
      CD40L IS NOT EXPRESSED ON T-CELLS INFILTRATING NON-HODGKINS-LYMPHOMA B-CELLS AND IS POORLY INDUCED AFTER STIMULATION

      Blood
    48. FINKE J; BLOOM T; RAYMAN P; SNYDER J; MCLAIN D; BUKOWSKI RM; HUSSEIN MA
      ACTIVATION OF THE TRANSCRIPTION FACTOR NF-KAPPA-B IN PERIPHERAL-BLOODT-CELLS FROM MULTIPLE-MYELOMA PATIENTS IS IMPAIRED AND MAY CONTRIBUTETO THEIR INCREASED SUSCEPTIBILITY TO ACTIVATION-INDUCED APOPTOSIS

      Blood
    49. BUKOWSKI RM; OLENCKI T; GUNN H; MCLAIN D; BUDD GT; SANDSTROM K; TUASON L; REDOVAN C; RAYMAN P; TUBBS R; RESTA D; ELSON P; FINKE J
      PHASE-I TRIAL OF SUBCUTANEOUS INTERLEUKIN-3 IN PATIENTS WITH REFRACTORY MALIGNANCY - HEMATOLOGICAL, IMMUNOLOGICAL, AND PHARMACODYNAMIC FINDINGS

      Clinical cancer research
    50. OLENCKI T; FINKE J; TUBBS R; TUASON L; GREENE T; MCLAIN D; SWANSON SJ; HERZOG P; STANLEY T; EDINGER M; BUDD GT; BUKOWSKI RM
      IMMUNOMODULATORY EFFECTS OF INTERLEUKIN-2 AND INTERLEUKIN-4 IN PATIENTS WITH MALIGNANCY

      Journal of immunotherapy with emphasis on tumor immunology
    51. GANAPATHI MK; WEIZER AK; BORSELLINO S; BUKOWSKI RM; GANAPATHI R; RICE T; CASEY G; KAWAMURA K
      RESISTANCE TO INTERLEUKIN-6 IN HUMAN NONSMALL CELL LUNG-CARCINOMA CELL-LINES - ROLE OF RECEPTOR COMPONENTS

      Cell growth & differentiation
    52. BUKOWSKI RM
      CURRENT APPROACHES IN CYTOPROTECTION - THE ROLE OF AMIFOSTINE (ETHYOL(R)) IN ALTERING AND AMELIORATING TOXICITIES IN CANCER-THERAPY

      European journal of cancer
    53. BUKOWSKI RM
      THE NEED FOR CYTOPROTECTION

      European journal of cancer
    54. BUDD GT; GANAPATHI R; BUKOWSKI RM; MURTHY S
      CLINICAL EFFECTS OF AMIFOSTINE (ETHYOL(R)) IN PATIENTS TREATED WITH CARBOPLATIN

      European journal of cancer
    55. BUKOWSKI RM
      AMIFOSTINE (ETHYOL(R)) - DOSING, ADMINISTRATION AND PATIENT-MANAGEMENT GUIDELINES

      European journal of cancer
    56. VARELLA D; TUASON L; PROFFITT MR; ESCALEIRA N; ALQUEZAR A; BUKOWSKI RM
      HIV-INFECTION AMONG BRAZILIAN TRANSVESTITES IN A PRISON POPULATION

      AIDS patient care
    57. TANNENBAUM CS; WICKER N; ARMSTRONG D; TUBBS R; FINKE J; BUKOWSKI RM; HAMILTON TA
      CYTOKINE AND CHEMOKINE EXPRESSION IN TUMORS OF MICE RECEIVING SYSTEMIC THERAPY WITH IL-12

      The Journal of immunology
    58. WOS E; OLENCKI T; TUASON L; BUDD GT; PEEREBOOM D; SANDSTROM K; MCLAIN D; FINKE J; BUKOWSKI RM
      PHASE-II TRIAL OF SUBCUTANEOUSLY ADMINISTERED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA

      Cancer
    59. BUDD GT; SAMUELS B; GOCKERMAN J; BAKER L; MARGOLIN K; ZALUPSKI M; FELSER J; JOHNSON B; ISAACS R; BUKOWSKI RM
      RANDOMIZED TRIAL OF MAID (MESNA, ADRIAMYCIN, IFOSFAMIDE, DECARBAZINE)CHEMOTHERAPY WITH G-CSF ALONE OR WITH G-CSF PLUS VARYING DOSES OF INTERLEUKIN-6 (IL-6)

      Blood
    60. HUSSEIN MA; SNYDER J; RAYMAN P; MCLAIN DA; FINKE J; BUKOWSKI RM
      IL-2 MAINTENANCE (MN) THERAPY IN MULTIPLE-MYELOMA (MM) - CD4 COUNT AND CD4 CD8 RATIO ABNORMALITIES MIGHT PREDICT A POOR OUTCOME GROUP/

      Blood
    61. HUSSEIN MA; FINKE J; RAYMAN P; BLOOM T; SYNDER J; MCLAIN DA; BUKOWSKI RM
      SIGNAL-TRANSDUCTION ABNORMALITIES IN PERIPHERAL-BLOOD T-CELLS IN PLASMA-CELL DYSCRASIA (PCD) PATIENTS (PTS)

      Blood
    62. BUKOWSKI RM; DON W; REDOVAN C; MCLAIN D; SANDSTROM K; OLENCKI T; BUDD GT; PEEREBOOM D; GRIFFIN T; TANNENBAUM C; FINKE JK
      INDUCTION OF THE CXC CHEMOKINES IP-10 AND MIG IN PATIENTS (PTS) RECEIVING RHUIL-12 OR RIL-2

      Blood
    63. KOLENKO VM; TUBBS RR; BUKOWSKI RM; FINKE JH
      ALTERED IL2 SIGNAL-TRANSDUCTION IN T-LYMPHOCYTES INFILTRATING HUMAN RENAL-CELL CARCINOMA

      The FASEB journal
    64. BUKOWSKI RM
      UNTITLED

      Cleveland Clinic journal of medicine
    65. WANG Q; REDOVAN C; TUBBS R; OLENCKI T; KLEIN E; KUDOH S; FINKE J; BUKOWSKI RM
      SELECTIVE CYTOKINE GENE-EXPRESSION IN RENAL-CELL CARCINOMA TUMOR-CELLS AND TUMOR-INFILTRATING LYMPHOCYTES

      International journal of cancer
    66. KOLENKO VM; TUBBS RR; NOVICK A; BUKOWSKI RM; FINKE JH
      IMPAIRED IL2R SIGNALING IN TUMOR-INFILTRATING LYMPHOCYTES

      Blood
    67. SMITH H; HUSSEIN MA; SANDSTROM K; HAYS A; BUKOWSKI RM
      DIVERSE BIOLOGIC ACTIVITIES OF GM-CSF IN MULTIPLE-MYELOMA

      Blood
    68. RICE TW; TUBBS RR; HOELTGE GA; KIRBY TJ; MEEKER DP; MEDENDORP SV; BUKOWSKI RM
      EXPRESSION OF BLOOD-GROUP ANTIGEN A BY STAGE-I NONSMALL CELL LUNG CARCINOMAS

      The Annals of thoracic surgery
    69. OLENCKI T; FINKE J; BUKOWSKI RM
      INTERLEUKIN-6 - POTENTIAL CLINICAL-APPLICATIONS IN CANCER-THERAPY

      CLINICAL IMMUNOTHERAPEUTICS
    70. BUKOWSKI RM; MURTHY SA; FINKE J; CAULFIELD MJ; TUBBS R; HERZOG P; STANLEY J; EDINGER M; TUASON L; MCLAIN D; BUDD GT; OLENCKI T; GANAPATHI R
      PHASE-I TRIAL OF CISPLATIN, WR-2721, AND THE MURINE MONOCLONAL-ANTIBODY R24 IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND BIOLOGIC EFFECTS

      Journal of immunotherapy with emphasis on tumor immunology
    71. FINKE JH; RAYMAN P; HART L; ALEXANDER JP; EDINGER MG; TUBBS RR; KLEIN E; TUASON L; BUKOWSKI RM
      CHARACTERIZATION OF TUMOR-INFILTRATING LYMPHOCYTE SUBSETS FROM HUMAN RENAL-CELL CARCINOMA - SPECIFIC REACTIVITY DEFINED BY CYTOTOXICITY, INTERFERON-GAMMA SECRETION, AND PROLIFERATION

      Journal of immunotherapy with emphasis on tumor immunology
    72. BUKOWSKI RM; OLENCKI T; MCLAIN D; FINKE JH
      PLEIOTROPIC EFFECTS OF CYTOKINES - CLINICAL AND PRECLINICAL STUDIES

      Stem cells
    73. BUDD GT; LORENZI V; GANAPATHI R; ADELSTEIN D; PELLEY R; OLENCKI T; MCLAIN D; BUKOWSKI RM
      AMIFOSTINE - POTENTIAL FOR CLINICALLY USEFUL CYTOPROTECTION

      Supportive care in cancer
    74. BUKOWSKI RM; BUDD GT; GIBBONS JA; BAUER RJ; CHILDS A; ANTAL J; FINKE J; TUASON L; LORENZI V; MCLAIN D; TUBBS R; EDINGER M; THOMASSEN MJ
      PHASE-I TRIAL OF SUBCUTANEOUS RECOMBINANT MACROPHAGE-COLONY-STIMULATING FACTOR - CLINICAL AND IMMUNOMODULATORY EFFECTS

      Journal of clinical oncology
    75. ADELSTEIN DJ; RICE TW; BOYCE GA; SIVAK MV; VANKIRK MA; KIRBY TJ; VANSTOLK RU; BUKOWSKI RM
      ADENOCARCINOMA OF THE ESOPHAGUS AND GASTROESOPHAGEAL JUNCTION - CLINICAL AND PATHOLOGICAL ASSESSMENT OF RESPONSE TO INDUCTION CHEMOTHERAPY

      American journal of clinical oncology
    76. BHATIA A; RICE TW; MCLAIN D; HERZOG P; BUDD GT; MURTHY S; KIRBY TJ; BUKOWSKI RM
      A PHASE-I TRIAL OF INTRAPLEURAL RECOMBINANT HUMAN INTERFERON-ALPHA (RHUIFN-ALPHA-2B) IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS

      Journal of cancer research and clinical oncology
    77. BUDD GT; HERZOG P; BUKOWSKI RM
      PHASE I II TRIAL OF DIPYRIDAMOLE, 5-FLUOROURACIL, LEUKOVORIN, AND MITOXANTRONE IN METASTATIC BREAST-CANCER/

      Investigational new drugs
    78. BUKOWSKI RM
      BIOLOGIC THERAPY IN PATIENTS RECEIVING SALVAGE TREATMENT

      Seminars in oncology
    79. SAMPAIO CA; MCLAIN D; KLEIN E; BUKOWSKI RM
      RENAL MASSES SIMULATING PRIMARY RENAL-CELL CARCINOMA IN PATIENTS WITHADVANCED MALIGNANCIES

      The Journal of urology
    80. KUDOH S; STANLEY J; EDINGER MG; TUBBS RR; KLEIN E; BUKOWSKI RM; FINKE JH
      T-LYMPHOCYTES INFILTRATING RENAL-CELL CARCINOMA HAVE A REDUCED EXPRESSION OF TRANSFERRIN RECEPTOR

      International journal of cancer
    81. TOCKMAN MS; EROZAN YS; GUPTA P; PIANTADOSI S; MULSHINE JL; RUCKDESCHEL JC; BUKOWSKI RM; LAD T; ETTINGER DS; DESLAURIERS J; GINSBERG R; KELLY K; HOLMES EC; MUGGIA F; ROTH JA; JOHNSTON M; MCKNEALLY MF
      THE EARLY DETECTION OF 2ND PRIMARY LUNG CANCERS BY SPUTUM IMMUNOSTAINING

      Chest
    82. KARNIK PS; KULKARNI S; LIU XP; BUDD GT; BUKOWSKI RM
      ESTROGEN-RECEPTOR MUTATIONS IN TAMOXIFEN-RESISTANT BREAST-CANCER

      Cancer research
    83. BUKOWSKI RM; TANGEN CM; PETERSON RF; TAYLOR SA; RINEHART JJ; EYRE HJ; RIVKIN SE; FLEMING TR; MACDONALD JS
      PHASE-II TRIAL OF DIMETHYLTRIAZENOIMIDAZOLE CARBOXAMIDE IN PATIENTS WITH METASTATIC CARCINOID - A SOUTHWEST-ONCOLOGY-GROUP STUDY

      Cancer
    84. BUKOWSKI RM; OLENCKI T; MCLAIN D; TUASON L; BUDD GT; SANDSTROM K; RAYMAN P; GUNN H; LEVITT D; FINKE J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT INTERLEUKIN-3 (RHIL-3) FOLLOWING SUBCUTANEOUS (SQ) ADMINISTRATION TO PATIENTS WITH REFRACTORY MALIGNANCIES

      Blood
    85. WOS E; OLENCKI T; BUDD GT; PEEREBOOM D; FINKE J; WOOD L; MCLAIN D; TUBBS R; REDOVAN C; EDINGER M; LEVITT D; BUKOWSKI RM
      HEMATOLOGIC EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHUGM-CSF) AND INTERLEUKIN-6 (RHIL-6) ADMINISTERED TO PATIENTS WITH MALIGNANCY

      Blood
    86. THOMASSEN MJ; ANTAL JM; CONNORS MJ; MCLAIN D; SANDSTROM K; MEEKER DP; BUDD GT; LEVITT D; BUKOWSKI RM
      IMMUNOMODULATORY EFFECTS OF RECOMBINANT INTERLEUKIN-3 TREATMENT ON HUMAN ALVEOLAR MACROPHAGES AND MONOCYTES

      Journal of immunotherapy with emphasis on tumor immunology
    87. BUKOWSKI RM; MURTHY S; MCLAIN D; FINKE J; ANDRESEN S; TUBBS R; BAUER L; GIBSON V; BUDD GT; THOMASSEN MJ
      PHASE-I TRIAL OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH LUNG-CANCER - CLINICAL AND IMMUNOLOGICAL EFFECTS

      Journal of immunotherapy with emphasis on tumor immunology
    88. BUDD GT; GANAPATHI R; BAUER L; MURTHY S; ADELSTEIN D; WEICK J; GIBSON V; MCLAIN D; SERGI J; BUKOWSKI RM
      PHASE-I STUDY OF WR-2721 AND CARBOPLATIN

      European journal of cancer
    89. LAUFMAN LR; BUKOWSKI RM; COLLIER MA; SULLIVAN BA; MCKINNIS RA; CLENDENNIN NJ; GUASPARI A; BRENCKMAN WD
      A RANDOMIZED, DOUBLE-BLIND TRIAL OF FLUOROURACIL PLUS PLACEBO VERSUS FLUOROURACIL PLUS ORAL LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL-CANCER

      Journal of clinical oncology
    90. BUKOWSKI RM; YOUNG J; GOODMAN G; MEYERS F; ISSELL BF; SERGI JS; MCLAIN D; FYFE G; FINKE J
      POLYETHYLENE-GLYCOL CONJUGATED INTERLEUKIN-2 - CLINICAL AND IMMUNOLOGICAL EFFECTS IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA

      Investigational new drugs
    91. BUDD GT; BUKOWSKI RM; LICHTIN A; BAUER L; VANKIRK P; GANAPATHI R
      PHASE-II TRIAL OF DOXORUBICIN AND TRIFLUOPERAZINE IN METASTATIC BREAST-CANCER

      Investigational new drugs
    92. BUKOWSKI RM
      MANAGEMENT OF ADVANCED AND EXTRAGONADAL GERM-CELL TUMORS (CORRECTED VERSION OF LA258)

      Urologic clinics of North America
    93. BUKOWSKI RM
      MANAGEMENT OF ADVANCED AND EXTRAGONADAL GERM-CELL TUMORS

      Urologic clinics of North America
    94. FINKE JH; ZEA AH; STANLEY J; LONGO DL; MIZOGUCHI H; TUBBS RR; WILTROUT RH; OSHEA JJ; KUDOH S; KLEIN E; BUKOWSKI RM; OCHOA AC
      LOSS OF T-CELL RECEPTOR ZETA-CHAIN AND P56(LCK) IN T-CELLS INFILTRATING HUMAN RENAL-CELL CARCINOMA

      Cancer research
    95. JANIK JE; SZNOL M; URBA WJ; FIGLIN R; BUKOWSKI RM; FYFE G; PIERCE WC; BELLDEGRUN A; SHARFMAN WH; SMITH JW; LONGO DL
      ERYTHROPOIETIN PRODUCTION - A POTENTIAL MARKER FOR INTERLEUKIN-2 INTERFERON-RESPONSIVE TUMORS

      Cancer
    96. DEMETRI GD; BUKOWSKI RM; SAMUELS B; GORDON M; ANTMAN K; MERICA EA; SAMUEL S; CAMPION M; LEVITT D; ISAACS R
      STIMULATION OF THROMBOPOIESIS BY RECOMBINANT HUMAN INTERLEUKIN-6 (IL-6) PRE-CHEMOTHERAPY AND POSTCHEMOTHERAPY IN PREVIOUSLY UNTREATED SARCOMA PATIENTS WITH NORMAL HEMATOPOIESIS

      Blood
    97. OLENCKI T; BUDD GT; MURTHY S; FINKE J; HERZOG P; MCLAIN D; TUBBS R; TUASON L; EDINGER M; LEVITT D; BUKOWSKI RM
      CYTOKINE GENE-EXPRESSION AND SECRETION - EFFECTS OF RHIL-6 IN CANCER-PATIENTS

      Blood
    98. CASE DC; BUKOWSKI RM; CAREY RW; FISHKIN EH; HENRY DH; JACOBSON RJ; JONES SE; KELLER AM; KUGLER JW; NICHOLS CR; SALMON SE; SILVER RT; STORNIOLO AM; WAMPLER GL; DOOLEY CM; LARHOLT KM; NELSON RA; ABELS RI
      RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY FOR ANEMIC CANCER-PATIENTS ON COMBINATION CHEMOTHERAPY

      Journal of the National Cancer Institute
    99. WOOLLEY PV; NAUTA R; SMITH FP; LINDBLAD AS; PETRELLI N; HERRERA L; DOUGLASS HO; MAYER RJ; BRUCKNER HW; DALTON J; BONADONNA G; GENNARI L; HALL TC; WEAVER DW; LEICHMAN L; KALSER MH; BENEDETTO P; MUGGIA FM; GREEN M; GREENWALD E; LEVIN B; GAYNOR E; HARRIS J; MARSH JC; BARWICK K; KNOWLTON AH; LIVSTONE EM; BUKOWSKI RM; LOUTFI A; RAMIREZ G; THOMAS PRM
      RADIATION-THERAPY AND FLUOROURACIL WITH OR WITHOUT SEMUSTINE FOR THE TREATMENT OF PATIENTS WITH SURGICAL ADJUVANT ADENOCARCINOMA OF THE RECTUM

      Journal of clinical oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/10/20 alle ore 03:11:24